Submitted:
09 April 2025
Posted:
10 April 2025
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Inflammation
2.1. Phospholipid Metabolites in Inflammation
2.2. Markers for Inflammation
2.3. Sphingolipid Metabolites in Inflammation
2.4. Cholesterol Metabolites in Inflammation
3. Cross-Talk Among Phospholipid, Sphingolipid, Cholesterol Metabolites in Inflammation
4. Conclusion
Author Contributions
Funding
Data Availability Statement
Conflicts of Interest
References
- Farooqui AA, Horrocks LA, Farooqui T. Glycerophospholipids in brain: their metabolism, incorporation into membranes, functions, and involvement in neurological disorders. Chem. Phys. Lipids 2000; 106:1-29.
- Farooqui, A.A. Hot Topics in Neural Membrane Lipidology; 2009, Springer, New York.
- Raghu P. Functional diversity in a lipidome. Proc. Natl. Acad. Sci. U. S. A, 2020; 117: 11191–11193.
- Harayama, T.; Riezman, H. Understanding the diversity of membrane lipid composition. Nat. Rev. Mol. Cell Biol. 2018, 19, 281–296; Correction in Nat. Rev. Mol. Cell Biol. 2019, 20, 715. [CrossRef]
- Dennis WD, Norris PC. Eicosanoid Storm in Infection and Inflammation. Nat Rev Immunol. 2015; 15: 511-523.
- Calder PC (2017) Omega-3 fatty acids and inflammatory processes: from molecules to man. Biochem Soc Trans 2017; 45: 1105–1115.
- Medzhitov, R. Inflammation 2010: New Adventures of an Old Flame. Cell 2010, 140, 771–776. [CrossRef]
- Furman, D.; Campisi, J.; Verdin, E.; Carrera-Bastos, P.; Targ, S.; Franceschi, C.; Ferrucci, L.; Gilroy, D.W.; Fasano, A.; Miller, G.W.; et al. Chronic inflammation in the etiology of disease across the life span. Nat. Med. 2019, 25, 1822–1832. [CrossRef]
- Newton K, Dixit VM. Signaling in innate immunity and inflammation. Cold Spring Harb Perspect Biol. 2012;4: a006049.
- Akira, S.; Uematsu, S.; Takeuchi, O. Pathogen recognition and innate immunity. Cell 2006, 124, 783–801. [CrossRef]
- Cignarella A, Bolego C. Innate Immunity in Inflammation. In: Riccardi C, Levi-Schaffer F, Tiligada E, editors. Immunopharmacology and Inflammation. Cham: Springer International Publishing p. 179–90, 2018.
- Kennedy, B.K.; Berger, S.L.; Brunet, A.; Campisi, J.; Cuervo, A.M.; Epel, E.S.; Franceschi, C.; Lithgow, G.J.; Morimoto, R.I.; Pessin, J.E.; et al. Geroscience: Linking Aging to Chronic Disease. Cell 2014, 159, 709–713. [CrossRef]
- Chen, Y.-H.; Wu, K.-H.; Wu, H.-P. Unraveling the Complexities of Toll-like Receptors: From Molecular Mechanisms to Clinical Applications. Int. J. Mol. Sci. 2024, 25, 5037. [CrossRef]
- Schroder K, Tschopp J. The inflammasomes. Cell. 2010; 140:821–832.
- Elliott, E.I.; Sutterwala, F.S. Initiation and perpetuation of NLRP3 inflammasome activation and assembly. Immunol. Rev. 2015, 265, 35–52. [CrossRef]
- Netea-Maier, R.T.; Plantinga, T.S.; van de Veerdonk, F.L.; Smit, J.W.; Netea, M.G. Modulation of inflammation by autophagy: Consequences for human disease. Autophagy 2016, 12, 245–260. [CrossRef]
- Farooqui, A.A. Inflammation and Oxidative Stress in Neurological Disorders; Springer Nature: Dordrecht, GX, Netherlands, 2014; ISBN: .
- Wood PL. Neuroinflammation: Mechanisms and Management, Humana Press, Totowa, New Jersey, 1998.
- Ramos-González EJ, Bitzer-Quintero OK, Ortiz G, Hernández-Cruz JJ, Ramírez-Jirano LJ. Relationship between inflammation and oxidative stress and its effect on multiple sclerosis. Neurologia (Engl Ed). 2024 ;39: 292-301.
- Serhan, C.N.; Savill, J. Resolution of inflammation: the beginning programs the end. Nat. Immunol. 2005, 6, 1191–1197. [CrossRef]
- Serhan, C.N.; Levy, B.D. Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators. J. Clin. Investig. 2018, 128, 2657–2669. [CrossRef]
- Vidar Hansen T, Serhan CN. Protectins: Their biosynthesis, metabolism, and structure-function. Biochem Pharmacol. 2022; 206:115330.
- Zhang, W.; Xiao, D.; Mao, Q.; Xia, H. Role of neuroinflammation in neurodegeneration development. Signal Transduct. Target. Ther. 2023, 8, 1–32. [CrossRef]
- Farooqui AA, Farooqui T. Phospholipids, Sphingolipids, and Cholesterol-Derived Lipid Mediators and Their Role in Neurological Disorders. Int J Mol Sci 2024; 25: 10672.
- Phillis, J.W.; Horrocks, L.A.; Farooqui, A.A. Cyclooxygenases, lipoxygenases, and epoxygenases in CNS: Their role and involvement in neurological disorders. Brain Res. Rev. 2006, 52, 201–243. [CrossRef]
- Lautier J-L, Wautier M-P. Pro- and Anti-Inflammatory Prostaglandins and Cytokines in Humans: A Mini Review. Int J Mol Sci. 2023; 24:9647.
- Ricciotti E, FitzGerald GA. Prostaglandins and Inflammation. Arterioscler Thromb Vasc Biol. 2011;1: 986–1000.
- Kitatani, K.; Idkowiak-Baldys, J.; Hannun, Y.A. The sphingolipid salvage pathway in ceramide metabolism and signaling. Cell. Signal. 2008, 20, 1010–1018. [CrossRef]
- Nixon, G.F. Sphingolipids in inflammation: pathological implications and potential therapeutic targets. Br. J. Pharmacol. 2009, 158, 982–993. [CrossRef]
- Ong WY, Herr DR, Farooqui T, Ling EA, Farooqui AA. Role of sphingomyelinases in neurological disorders Expert Opin Ther Targets. 2015; 19:1725-1742.
- Schütze S, Potthoff K, Machleidt T, Berkovic D, Wiegmann K, Krönke M. TNF activates NF-κB by phosphatidylcholine-specific phospholipase C-induced ‘acidic’ sphingomyelin breakdown. Cell. 1992;71: 765–776.
- Boyd, R.J.; Avramopoulos, D.; Jantzie, L.L.; McCallion, A.S. Neuroinflammation represents a common theme amongst genetic and environmental risk factors for Alzheimer and Parkinson diseases. J. Neuroinflammation 2022, 19, 1–20. [CrossRef]
- Ikonen, E.; Zhou, X. Cholesterol transport between cellular membranes: A balancing act between interconnected lipid fluxes. Dev. Cell 2021, 56, 1430–1436. [CrossRef]
- Zhang, J.; Liu, Q. Cholesterol metabolism and homeostasis in the brain. Protein Cell 2015, 6, 254–264. [CrossRef]
- Wheless JW, Rho JM. Role of cholesterol metabolism and homeostasis in the brain hyperexcitability. Epilepsia 2025; 66; 33-46.
- Lawrence, T. The Nuclear Factor NF-kappa B Pathway in Inflammation. Cold Spring Harb. Perspect. Biol. 2009, 1, a001651. [CrossRef]
- Pariente, A.; Peláez, R.; Pérez-Sala, A.; Larráyoz, I.M. Inflammatory and cell death mechanisms induced by 7-ketocholesterol in the retina. Implications for age-related macular degeneration. Exp. Eye Res. 2019, 187, 107746. [CrossRef]
- Andersen A, Campo A, Fulton E, Corwin A, Jerome III WG, O’Connor MS, 7-Ketocholesterol in disease and aging. Redox Biol. 2019; 29:101380.
- Freeman, N.E.; Rusinol, A.E.; Linton, M.; Hachey, D.L.; Fazio, S.; Sinensky, M.S.; Thewke, D. Acyl-coenzyme A:cholesterol acyltransferase promotes oxidized LDL/oxysterol-induced apoptosis in macrophages. J. Lipid Res. 2005, 46, 1933–1943. [CrossRef]
- Weigel, T.K.; Kulas, J.A.; Ferris, H.A. Oxidized cholesterol species as signaling molecules in the brain: diabetes and Alzheimer’s disease. Neuronal Signal. 2019, 3, NS20190068. [CrossRef]
- Fitzgerald, K.A.; Kagan, J.C. Toll-like Receptors and the Control of Immunity. Cell 2020, 180, 1044–1066. [CrossRef]
- Kihara, A.; Igarashi, Y. Cross Talk between Sphingolipids and Glycerophospholipids in the Establishment of Plasma Membrane Asymmetry. Mol. Biol. Cell 2004, 15, 4949–4959. [CrossRef]
- Kihara, A. Sphingosine 1-phosphate is a key metabolite linking sphingolipids to glycerophospholipids. Biochim. et Biophys. Acta (BBA) - Mol. Cell Biol. Lipids 2014, 1841, 766–772. [CrossRef]
- Sukhorukov, V.N.; Orekhov, A.N. Molecular Aspects of Inflammation and Lipid Metabolism in Health and Disease: The Role of the Mitochondria. Int. J. Mol. Sci. 2024, 25, 6299. [CrossRef]
- Wajner, M.; Amaral, A.U. Mitochondrial dysfunction in fatty acid oxidation disorders: insights from human and animal studies. Biosci. Rep. 2016, 36, e00281. [CrossRef]
- Pradeepkiran, J.A.; Reddy, P.H. Defective mitophagy in Alzheimer's disease. Ageing Res. Rev. 2020, 64, 1–101191. [CrossRef]
- Vringer, E.; Tait, S.W.G. Mitochondria and cell death-associated inflammation. Cell Death Differ. 2022, 30, 304–312. [CrossRef]
- Hamzeh, O.; Rabiei, F.; Shakeri, M.; Parsian, H.; Saadat, P.; Rostami-Mansoor, S. Mitochondrial dysfunction and inflammasome activation in neurodegenerative diseases: Mechanisms and therapeutic implications. Mitochondrion 2023, 73, 72–83. [CrossRef]
- Lee, Y.; Hirose, H.; Ohneda, M.; Johnson, J.H.; McGarry, J.D.; Unger, R.H. Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships. Proc. Natl. Acad. Sci. 1994, 91, 10878–10882. [CrossRef]
- Malhi, H.; Gores, G.J. Molecular Mechanisms of Lipotoxicity in Nonalcoholic Fatty Liver Disease. Semin. Liver Dis. 2008, 28, 360–369. [CrossRef]
- Yoon, H.; Shaw, J.L.; Haigis, M.C.; Greka, A. Lipid metabolism in sickness and in health: Emerging regulators of lipotoxicity. Mol. Cell 2021, 81, 3708–3730. [CrossRef]
- Lytrivi, M.; Castell, A.-L.; Poitout, V.; Cnop, M. Recent Insights Into Mechanisms of β-Cell Lipo- and Glucolipotoxicity in Type 2 Diabetes. J. Mol. Biol. 2020, 432, 1514–1534. [CrossRef]
- Goldberg, I.J.; Trent, C.M.; Schulze, P.C. Lipid Metabolism and Toxicity in the Heart. Cell Metab. 2012, 15, 805–812. [CrossRef]





| Parameters | Acute inflammation | Chronic inflammation |
|---|---|---|
| Color | Redness | No color |
| Rate of development | Rapid | Slow |
| Perception | Pain | No pain |
| Levels of cytokines | High | Low |
| Levels of chemokines | High | Low |
| Levels of eicosanoids | High | Low |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).